Real-world Patient Reported Outcomes Among Patients Treated With Camzyos (COMPASS-HCM)

Bristol-Myers Squibb (BMS)

Status

Enrolling

Conditions

Obstructive Hypertrophic Cardiomyopathy

Treatments

Drug: Mavacamten

Study type

Observational

Funder types

Industry

Identifiers

NCT06551129

CV027-1002

Details and patient eligibility

About

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.

Enrollment

118 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants ≥18 years of age.
Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy
Provided informed consent to participate in the study

Exclusion criteria

Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors
Treated for >7 days with mavacamten by the day of completing the baseline survey
Enrolled in any clinical trials at the time of or within the six-month period prior to the screening
Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening
Had stroke or transient ischemic attack within the six-month period prior to the screening
Had moderate-to-severe lung disease which impacted the ability to perform daily activities of living and ability to breathe
Had major lung (thoracic) or heart (cardiac) surgery within the six-month period prior to the screening
Scheduled for a major surgery for the next three months, such as joint surgeries including hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eye surgeries, brain surgeries, and any other major surgeries that require general anesthesia and at least an overnight hospital stay
Hospitalized requiring an overnight stay at the time of or within the two-week period prior to the screening